Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3,431 | $2,189 | $2,018 | $2,033 |
| - Cash | $665 | $68 | $48 | $72 |
| + Debt | $451 | $6 | $4 | $7 |
| Enterprise Value | $3,217 | $2,127 | $1,974 | $1,968 |
| Revenue | $115 | $48 | $45 | $43 |
| % Growth | 142.4% | 5.1% | 5.9% | – |
| Gross Profit | $91 | $45 | $40 | $40 |
| % Margin | 78.5% | 93.9% | 89.3% | 93.4% |
| EBITDA | $149 | $21 | -$41 | -$30 |
| % Margin | 129.2% | 43.9% | -89.4% | -69.3% |
| Net Income | $117 | $5 | -$42 | -$31 |
| % Margin | 101.6% | 10.2% | -93.6% | -72.6% |
| EPS Diluted | 5.68 | 0.24 | -2.21 | -1.64 |
| % Growth | 2,266.7% | 110.9% | -34.8% | – |
| Operating Cash Flow | $13 | $16 | -$26 | $28 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$1 |
| Free Cash Flow | $13 | $16 | -$26 | $28 |